SBIR/STTR Research Award

Development of Carbon Nanoencapsulates for Biomedicine

Award identifier 21c5af97674b7255a0b56661f880d3a841d565aacc66276c75a6618842ce0feaAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$180,346

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TDA RESEARCH, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
MK5ANJVWVZK7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

A newly discovered class of nanoscale materials, the metal-carbon nanoencapsulates, has considerable potential to improve on current molecular-based MRI contrast enhancing agents. Metal-carbon nanoencapsulates are 2 nm diameter and larger particles in which graphitic carbon layers encase single crystals of metals or metal carbides. Their continuous graphitic carbon shells are several layers thick and highly stable. This shell protects the metal nanocrystal from oxygen and water, prevents the metal from leaving the encapsulate, allows magnetic interactions between the metal and exterior molecules, and provides a scaffolding for chemical derivitization. These physical characteristics impart significant advantages to metal-carbon nanoencapsulates and will result in a safer, more effective class of novel MRI contrast enhancing agents based on metal-carbon nanoencapsulates. The nanoencapsulates will be aminated, allowing for solubilization and coupling reactions on the surface of the nanoencapsulate. The relaxivity characterisitics of gadolinium containing solubilized nanoencapsulates with be evaluated, and the covalent conjugation of proteins will be tested. Potential applications for these nanoencapsulate contrast agents include imaging of the blood pool, RES, cancerous lesions, and targeted imaging of receptors and gene expression. PROPOSED COMMERCIAL APPLICATION: The development of a new class of potent MRI contrast enhancing agents based on magnetic metal-carbon nanoencapsulates with higher stabilities, higher relaxivities, lower required in vivo concentrations and novel utility in target-specific imaging applications will have substantial commercial impact. Once fully developed, these safer and more powerful contrast enhancing agents will be in demand for clinical use in MRI laboratories and hospitals around the country in applications like MR angiography, imaging of reticuloendothelial system components, imaging of cancerous lesions with targeted agents, and for imaging gene expression and other receptors.

Technology keywords

Not reported

Research funding history

951 SBIR/STTR records share this UEI (1988–2026). Reported award amounts total $317,960,224. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Energy, National Aeronautics and Space Administration, Environmental Protection Agency, National Science Foundation, Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.